GSK said on Thursday two combination therapies with its cancer drug, Blenrep, have received approval from British authorities ...

Anyone in the U.S. who bought any flavor Robitussin product containing dextromethorphan (or DXM) and labeled as “non-drowsy” between Feb. 16, 2016, and Jan. 21 are eligible to file a claim, according ...

British pharmaceutical giant GSK has not met required ethical and regulatory standards in the marketing and prescription ...

London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves ...

GSK has continued to flesh out its neuroscience strategy with a 2 billion pound sterling ($2.5 billion) deal to use a South Korean company’s tech to bypass the blood-brain barrier. ABL Bio has ...

LOS ANGELES, April 7, 2025 /PRNewswire/ -- The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against GSK plc ("GSK" or "the Company ...

ABL Bio Inc. announced April 7 that it sealed a potential £2.075 billion (US$2.65 billion) license deal with GSK plc, granting GSK global rights to use ABL’s blood-brain barrier (BBB) penetrating ...

GSK and Pfizer said in the filing that they would dismiss the case with prejudice, which means it cannot be refiled. Spokespeople for the companies did not immediately respond to requests for ...

(Reuters) -British pharmaceutical giant GlaxoSmithKline and rival Pfizer have agreed to end a lawsuit that alleged Pfizer's respiratory syncytial virus (RSV) vaccine Abrysvo violated GSK's patent ...

If you were a 23andMe customer, your genetic and personal information could be used in civil or criminal cases, targeted ...

The approval represents another step forward for Pfizer in the RSV vaccine market, where it competes with GSK’s Arexvy. While GSK has secured approval for older adults, it has not yet gained ...

NEW YORK, March 31, 2025 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of GSK plc (NYSE: GSK). Shareholders who purchased shares of GSK during the class period ...